New drug aims to outsmart resistant prostate cancer
NCT ID NCT06705686
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new oral drug called (R)-9bMS in about 18-30 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has stopped responding to hormone therapy. The drug works by blocking a protein called ACK1, which may help shrink tumors and boost the immune system's ability to fight cancer. The main goal is to check the drug's safety and find the best dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
(R)-9bMS (also called Mahatinib), a new targeted drug taken by mouth
What this could lead to
If this early trial shows the drug is safe and has anti-tumor activity, it could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 18-30 participants, so the main goal is safety, not effectiveness. The drug may not work well in humans or may cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect
RECRUITINGMadison, Wisconsin, 53792, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••